Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The sale of remaining rights to Allogene ends acrimony between the two companies.
Keyvibe-010 fails, but not for the reason you might have expected.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.